Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Published:2012-01-31 Issue:12 Volume:118 Page:3123-3127
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Huang Xuelin,Cortes Jorge,Kantarjian Hagop

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference15 articles.

1. United State life tables;Arias;Natl Vital Stat Rep,2010

2. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia;Tura;N Engl J Med,1994

3. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia;Hehlmann;Blood,1994

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

5. International Randomized Study of Interferon vs ST1571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract];Deininger;Blood,2009

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study;European Journal of Haematology;2024-09-12

3. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

4. Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia;Heliyon;2024-08

5. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23